Retinal toxicity after high-dose cisplatin therapy.

Because of increasing complaints of visual dysfunction, 13 patients with refractory or recently diagnosed ovarian carcinoma were evaluated for possible cisplatin-induced ophthalmologic toxicity. All patients had received high-dose cisplatin (200 mg/m2 in five divided daily doses) over two to four cycles. Eight patients (62%) developed symptoms of blurred vision and three (23%) also developed altered color perception. Retinal toxicity in the form of cone dysfunction was documented by electroretinography and color vision testing in 11 patients. Three patients were studied prospectively. Two patients who developed cone dysfunction had normal ophthalmologic exams before the initiation of chemotherapy or after one cycle of cisplatin, suggesting a causal relationship between cisplatin therapy and subsequent retinal abnormalities. Though visual acuity improved off therapy, color vision abnormalities persisted as long as 16 months beyond therapy.

[1]  S. Rivkin,et al.  High-dose cisplatin therapy for cancer of the ovary: neurotoxicity. , 1985, Annals of internal medicine.

[2]  K E Higgins,et al.  Spatial contrast sensitivity. Importance of controlling the patient's visibility criterion. , 1984, Archives of ophthalmology.

[3]  N. Javadpour,et al.  Treatment of poor prognosis nonseminomatous testicular cancer with a “high‐dose” platinum combination chemotherapy regimen , 1983, Cancer.

[4]  T. J. Walsh,et al.  Neurotoxic effects of cisplatin therapy. , 1982, Archives of neurology.

[5]  C. Cohen,et al.  Cerebral Blindness in Association with cis-Platinum Chemotherapy for Advanced Carcinoma of the Fallopian Tube , 1982, Obstetrics and gynecology.

[6]  A Uvijls,et al.  A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores. , 1982, American journal of ophthalmology.

[7]  S. Handel,et al.  A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. , 1982, Cancer research.

[8]  H. Muss,et al.  Cisplatin-associated cortical blindness. , 1981, Gynecologic oncology.

[9]  N. Bachur,et al.  Cis‐dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms , 1980, Cancer.

[10]  E. Wiltshaw,et al.  Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. , 1979, Cancer treatment reports.

[11]  P. Wiernik,et al.  Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. , 1978, Cancer treatment reports.

[12]  D. Cogan,et al.  Colorimetry by a new principle. , 1978, Archives of ophthalmology.

[13]  P. Gouras,et al.  A Ganzfeld stimulator for electroretinography. , 1976, A M A Archives of Ophthalmology.

[14]  G. Fishman,et al.  Acquired color vision defects. , 1971, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[15]  J Pokorny.  Basic concepts of color vision. , 1971, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[16]  A Linksz.  Color vision tests in clinical practice. , 1971, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[17]  P. Gouras.  Symposium on Electrophysiology: Electroretinography: Some Basic Principles , 1970 .

[18]  David Oliver Harrington,et al.  The visual fields: A textbook and atlas of clinical perimetry , 1976 .